Cong Peijie, Raffeld Mark, Teruya-Feldstein Julie, Sorbara Lynn, Pittaluga Stefania, Jaffe Elaine S
Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Blood. 2002 May 1;99(9):3376-82. doi: 10.1182/blood.v99.9.3376.
From 1992 to 2000, we identified 23 lymph node biopsies with focal germinal centers (GCs) containing centrocytes staining strongly for bcl-2 protein, whereas most of the remaining lymph node showed bcl-2-negative follicular hyperplasia. We propose the designation in situ localization of follicular lymphoma (FL) for this phenomenon. In 2 additional cases, bcl-2(+) follicles with features of in situ FL were identified in association with other low-grade B-cell lymphomas. To investigate the clonality of the bcl-2(+) follicles, we performed laser capture microdissection of bcl-2(+) and bcl-2 follicles from the same lymph node in 5 cases, and analyzed them in parallel by polymerase chain reaction (PCR) amplification of immunoglobulin heavy chain (IgH) genes. In 4 of 5 cases the bcl-2(+) follicles contained monoclonal IgH gene rearrangements, whereas the bcl-2(-) GCs exhibited a polyclonal ladder. A BCL2/JH gene rearrangement was detected in 6 of 14 (43%) evaluable cases. There were 5 patients with synchronous evidence of FL at another site. There were 13 patients who, without a prior diagnosis of FL, had clinical follow-up; one developed FL in an adjacent lymph node within one year, and 2 manifested FL at 13 and 72 months, respectively. There are 10 patients who have not yet shown other evidence of FL. These results suggest that at least close to half of these cases (8/18; 44%) represent homing to and early colonization of reactive GCs by FL. Other cases might represent FL at the earliest stage of development, or a preneoplastic event, requiring a second hit for neoplastic transformation. These findings provide insight into the pathophysiology of early FL, and illustrate the utility of immunohistochemistry for early diagnosis.
1992年至2000年期间,我们鉴定出23例淋巴结活检标本,其局灶性生发中心(GCs)中的中心细胞bcl-2蛋白染色呈强阳性,而其余大部分淋巴结表现为bcl-2阴性的滤泡性增生。我们建议将这种现象命名为滤泡性淋巴瘤(FL)的原位定位。在另外2例病例中,发现具有原位FL特征的bcl-2(+)滤泡与其他低级别B细胞淋巴瘤相关。为了研究bcl-2(+)滤泡的克隆性,我们对5例同一淋巴结中的bcl-2(+)和bcl-2(-)滤泡进行了激光捕获显微切割,并通过免疫球蛋白重链(IgH)基因的聚合酶链反应(PCR)扩增对其进行平行分析。5例中有4例bcl-2(+)滤泡含有单克隆IgH基因重排,而bcl-2(-)生发中心呈现多克隆条带。在14例可评估病例中的6例(43%)检测到BCL2/JH基因重排。有5例患者在另一部位同时出现FL证据。有13例患者在未预先诊断为FL的情况下进行了临床随访;1例在1年内其相邻淋巴结发生FL,2例分别在13个月和72个月时出现FL。有10例患者尚未出现FL的其他证据。这些结果表明,这些病例中至少近一半(8/18;44%)代表FL归巢至反应性生发中心并早期定植。其他病例可能代表FL发育的最早阶段,或一种肿瘤前事件,需要第二次打击才能发生肿瘤转化。这些发现为早期FL的病理生理学提供了见解,并说明了免疫组织化学在早期诊断中的实用性。